Biotech entity

CMS

organization

pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Acorn Energy, Inc., the most common co-covered peer. CMS appears in 1 tracked Biotech story from March 6, 2026. The tracked stories average 2 original sources each.

Last mentioned: Mar 19, 2026

Entity pulse

Recent coverage · CMS

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about CMS

pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Acorn Energy, Inc., the most common co-covered peer. CMS appears in 1 tracked Biotech story from March 6, 2026. The tracked stories average 2 original sources each.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering CMS. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning CMS 1

Pharma Neutral

CorMedix Q4 2025: DefenCath Commercialization Drives Growth Strategy

CorMedix Inc. (NASDAQ: CRMD) reported its Q4 2025 financial results, highlighting the successful commercial ramp-up of DefenCath, the first FDA-approved antimicrobial catheter lock solution. The company is focusing on securing major dialysis organization contracts and optimizing reimbursement pathways to solidify its market position.

2 sources

CMS is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.